Despite advances in treatment and clear guidelines, many patients with
diabetes are failing to achieve target glucose levels both in the
inpatient and outpatient setting. One of the main challenges posing a
barrier is clinical inertia preventing the initiation and
intensification of insulin therapy. Insulin therapy has been proven to
significantly reduce hemoglobin A1c levels in individuals with diabetes
and better manage hyperglycemia, yet countless studies show that insulin
initiation and intensification is frequently and inappropriately delayed.
This press release features multimedia. View the full release here:
who formed a business relationship last year, are partnering to offer a
complimentary webinar, “How
Technology Can Support Adoption of Best Practices for Inpatient and
Outpatient Insulin Management.” The webinar will discuss the current
challenges in initiating and managing insulin therapy, review the
recommended practices in both the inpatient and outpatient setting, and
discuss how technology can be used and implemented to benefit both
patients and providers.
You may register for the webinar here.
Tuesday, June 25, 2019 at 12:00 pm EST
Amy Butts PA-C, MPAS, CDE, BC-ADM, Endocrine Physician Assistant,
Mark Vanderwel, MD, Medical Director of the Pediatric Endocrinology
Division, Atrium Health
Discuss the difficulties that providers and patients have with
managing insulin dosing
Review the 2019 ADA Standards of Medical Care in Diabetes for insulin
Provide examples of how technology can support inpatient and
outpatient insulin titration
- Describe strategies to integrate technology into your environment
Following the live webinar, a recording will be available to download on monarchmedtech.com
within 24 hours of the live event.
About Monarch Medical Technologies
Monarch Medical Technologies is the leading provider of electronic
systems for inpatient glycemic management. Monarch’s EndoTool®
Glucose Management System offers personalized dosing recommendations for
intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared,
patented software suite, EndoTool has been chosen by more than 300
hospitals to provide unsurpassed patient-specific glycemic control
across a broad population of patients, and ultimately deliver better,
safer care. For more information, please visit monarchmedtech.com.
Voluntis creates digital therapeutics that empower people suffering from
chronic conditions to self- manage their treatment every day, thus
improving real-world outcomes. Combining mobile and web apps, Voluntis’
solutions deliver personalized recommendations to the patient and the
care team so that they can, for example, adjust treatment dosage, manage
side effects or monitor symptoms. These real- time recommendations are
based on digitized clinical algorithms. Leveraging its Theraxium
technology platform, Voluntis has designed and operates multiple digital
therapeutics, especially in diabetes and oncology. Voluntis has
long-standing partnerships with leading life science companies such as
Abbvie, AstraZeneca, Roche, Sanofi and Onduo. Based out of Boston and
Paris, France, Voluntis is a founding member of the Digital Therapeutics
Alliance. For further information: http://www.voluntis.com.
is traded on the Euronext Paris – Compartment C market
– ISIN: FR0004183960
Diabeo® is a registered trademark of Sanofi. Insulia® is a registered
trademark of Voluntis.
For further information: http://www.voluntis.com